HIV-1 structural proteins serve as PAMPs for TLR2 heterodimers significantly increasing infection and innate immune activation

Frontiers in Immunology

Volumn 6, Issue AUG, 2015, Pages

  Henrick, Bethany M ^a,b   Yao, Xiao Dan ^a   Rosenthal, Kenneth Lee ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human immunodeficiency virus type 1; Immune activation; Inflammation; Innate immunity; Pathogen associated molecular patterns; Pattern recognition receptors; TLR2 heterodimers; Toll like receptors

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; GLYCOPROTEIN GP 41; HETERODIMER; HIV 1 STRUCTURAL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PATHOGEN ASSOCIATED MOLECULAR PATTERN PROTEIN; PROTEIN P17; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CLONING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; DOT HYBRIDIZATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOPRECIPITATION; INNATE IMMUNITY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS DNA CELL DNA INTERACTION; VIRUS PATHOGENESIS; WESTERN BLOTTING;

EID: 84941282917     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00426     Document Type: Article

References (78)

1. Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 17:1881-8. doi:10.1097/01.aids.0000076311.76477.6e.
2. Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, Narváez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 104:942-7. doi:10.1182/blood-2003-09-3333.
3. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev (2013) 26:2-18. doi:10.1128/CMR.00050-12.
4. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol (2012) 10:655-66. doi:10.1038/nrmicro2848.
5. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 254:326-42. doi:10.1111/imr.12065.
6. Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev (2013) 254:78-101. doi:10.1111/imr.12079.
7. Paiardini M, Pandrea I, Apetrei C, Silvestri G. Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med (2009) 60:485-95. doi:10.1146/annurev.med.60.041807.123753.
8. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med (2009) 17:118-23.
9. Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis (2011) 53:1127-9. doi:10.1093/cid/cir628.
10. Guaraldi G, Prakash M, MoecklinghoffC, Stellbrink H-J. Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. AIDS Rev (2014) 16:75-89.
11. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis (2011) 53:1120-6. doi:10.1093/cid/cir627.
12. Lester RT, Yao X-D, Ball TB, McKinnon LR, Kaul R, Wachihi C, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (2008) 22:685-94. doi:10.1097/QAD.0b013e3282f4de35.
13. Armstrong JA, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet (1984) 2:370-2. doi:10.1016/S0140-6736(84)90540-3.
14. Tenner-Rácz K, Rácz P, Dietrich M, Kern P. Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy. Lancet (1985) 1:105-6. doi:10.1016/S0140-6736(85)91994-4.
15. Popovic M, Tenner-Racz K, Pelser C, Stellbrink H-J, van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2005) 102:14807-12. doi:10.1073/pnas.0506857102.
16. De Francesco MA, Caruso A, Fallacara F, Canaris AD, Dima F, Poiesi C, et al. HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS (1998) 12:245-52. doi:10.1097/00002030-199803000-00001.
17. De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci U S A (2002) 99:9972-7. doi:10.1073/pnas.142274699.
18. Chirmule N, Pahwa S. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev (1996) 60:386-406.
19. Nazli A, Kafka JK, Ferreira VH, Anipindi V, Mueller K, Osborne BJ, et al. HIV-1 gp120 induces TLR2-and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol (2013) 191:4246-58. doi:10.4049/jimmunol.1301482.
20. Caccuri F, Giagulli C, Bugatti A, Benetti A, Alessandri G, Ribatti D, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 109:14580-5. doi:10.1073/pnas.1206605109.
21. Yang B, Akhter S, Chaudhuri A, Kanmogne GD. HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling. Microvasc Res (2009) 77:212-9. doi:10.1016/j.mvr.2008.11.003.
22. Zhou C, Lu L, Tan S, Jiang S, Chen Y-H. HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. J Biol Chem (2011) 286:44869-77. doi:10.1074/jbc. M111.267393.
23. Terzieva V, Popova D, Kicheva M, Todorova Y, Markova R, Martinova F, et al. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART. Int Immunopharmacol (2009) 9:831-6. doi:10.1016/j.intimp.2009.03.009.
24. Renga B, Francisci D, Schiaroli E, Carino A, Cipriani S, D'Amore C, et al. The HIV matrix protein p17 promotes the activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2. PLoS One (2014) 9:e94798. doi:10.1371/journal.pone.0094798.
25. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, Arthos J, et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2007) 104:3396-401. doi:10.1073/pnas.0611353104.
26. Gringhuis SI, van der Vlist M, van den Berg LM, Dunnen den J, Litjens M, Geijtenbeek TBH. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol (2010) 11:419-26. doi:10.1038/ni.1858.
27. Beignon A-S, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-like receptor-viral RNA interactions. J Clin Invest (2005) 115:3265-75. doi:10.1172/JCI26032.
28. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303:1526-9. doi:10.1126/science.1093620.
29. Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis (2010) 202:S297-301. doi:10.1086/655657.
30. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature (2000) 406:782-7. doi:10.1038/35021228.
31. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol (2002) 20:197-216. doi:10.1146/annurev.immunol.20.083001.084359.
32. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem (2007) 141:137-45. doi:10.1093/jb/mvm032.
33. Barbeau B, Bernier R, Dumais N, Briand G, Olivier M, Faure R, et al. Activation of HIV-1 long terminal repeat transcription and virus replication via NF-κB-dependent and-independent pathways by potent phosphotyrosine phosphatase inhibitors, the peroxovanadium compounds. J Biol Chem (1997) 272:12968-77. doi:10.1074/jbc.272.20.12968.
34. Guan Y, Ranoa DRE, Jiang S, Mutha SK, Li X, Baudry J, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol (2010) 184:5094-103. doi:10.4049/jimmunol.0901888.
35. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A (2000) 97:13766-71. doi:10.1073/pnas.250476497.
36. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol (2006) 177:7094-102. doi:10.4049/jimmunol.177.10.7094.
37. Leoni V, Gianni T, Salvioli S, Campadelli-Fiume G. Herpes simplex virus glycoproteins gH/gL and gB bind toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-κB. J Virol (2012) 86:6555-62. doi:10.1128/JVI.00295-12.
38. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology (2004) 127:1513-24. doi:10.1053/j.gastro.2004.08.067.
39. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol (2002) 76:8729-36. doi:10.1128/JVI.76.17.8729-8736.2002.
40. Thibault S, Tardif MR, Barat C, Tremblay MJ. TLR2 signaling renders quiescent naive and memory CD4+ T cells more susceptible to productive infection with X4 and R5 HIV-type 1. J Immunol (2007) 179:4357-66. doi:10.4049/jimmunol.179.7.4357.
41. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, et al. Soluble forms of toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol (2003) 171:6680-9. doi:10.4049/jimmunol.171.12.6680.
42. Kuroishi T, Tanaka Y, Sakai A, Sugawara Y, Komine K-I, Sugawara S. Human parotid saliva contains soluble toll-like receptor (TLR) 2 and modulates TLR2-mediated interleukin-8 production by monocytic cells. Mol Immunol (2007) 44:1969-76. doi:10.1016/j.molimm.2006.09.028.
43. Dulay AT, Buhimschi CS, Zhao G, Oliver EA, Mbele A, Jing S, et al. Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J Immunol (2009) 182:7244-53. doi:10.4049/jimmunol.0803517.
44. Henrick BM, Nag K, Yao X-D, Drannik AG, Aldrovandi GM, Rosenthal KL. Milk matters: soluble toll-like receptor 2 (sTLR2) in breast milk significantly inhibits HIV-1 infection and inflammation. PLoS One (2012) 7:e40138. doi:10.1371/journal.pone.0040138.t001.
45. Henrick BM, Yao X-D, Drannik AG, Abimiku A, Rosenthal KL. Soluble toll-like receptor 2 is significantly elevated in HIV-1 infected breast milk and inhibits HIV-1 induced cellular activation, inflammation and infection. AIDS (2014) 28:2023-32. doi:10.1097/QAD.0000000000000381.
46. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol (2009) 485:395-405. doi:10.1007/978-1-59745-170-3_26.
47. Jain S, Rosenthal KL. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol (2011) 4(5):539-53. doi:10.1038/mi.2011.21.
48. Yao XD, Omange RW, Henrick BM, Lester RT, Kimani J, Ball TB, et al. Acting locally: innate mucosal immunity in resistance to HIV-1 infection in Kenyan commercial sex workers. Mucosal Immunol (2014) 7:268-79. doi:10.1038/mi.2013.44.
49. Drannik AG, Nag K, Yao X-D, Henrick BM, Jain S, Ball TB, et al. Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells. J Virol (2012) 86:4599-610. doi:10.1128/JVI.06561-11.
50. Thacker TC, Johnson FB. Binding of bovine parvovirus to erythrocyte membrane sialylglycoproteins. J Gen Virol (1998) 79(Pt 9):2163-9.
51. Mian MF, Ahmed AN, Rad M, Babaian A, Bowdish D, Ashkar AA. Length of dsRNA (poly I:C) drives distinct innate immune responses, depending on the cell type. J Leukoc Biol (2013) 94(5):1025-36. doi:10.1189/jlb.0312125.
52. Pereira CF, Boven LA, Middel J, Verhoef J, Nottet HS. Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions. J Leukoc Biol (2000) 68:423-8.
53. Ramis I, Roselló-Catafau J, Gómez G, Zabay JM, Fernández Cruz E, Gelpí E. Cyclooxygenase and lipoxygenase arachidonic acid metabolism by monocytes from human immune deficiency virus-infected drug users. J Chromatogr A (1991) 557:507-13. doi:10.1016/S0021-9673(01)87159-4.
54. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med (1991) 114:678-93. doi:10.7326/0003-4819-114-8-678.
55. Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell SB, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol (1998) 161:3195-201.
56. Heggelund L, Müller F, Lien E, Yndestad A, Ueland T, Kristiansen KI, et al. Increased expression of toll-like receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin Infect Dis (2004) 39:264-9. doi:10.1086/421780.
57. Mehandru S. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 200:761-70. doi:10.1084/jem.20041196.
58. Brenchley JM. CD4+ T Cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 200:749-59. doi:10.1084/jem.20040874.
59. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol (2006) 7:235-9. doi:10.1038/ni1316.
60. Thibault S, Fromentin R, Tardif MR, Tremblay MJ. TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology (2009) 6:42. doi:10.1186/1742-4690-6-42.
61. Chodisetti SB, Gowthaman U, Rai PK, Vidyarthi A, Khan N, Agrewala JN. Triggering through toll-like receptor 2 limits chronically stimulated T-helper type 1 cells from undergoing exhaustion. J Infect Dis (2015) 211:486-96. doi:10.1093/infdis/jiu472.
62. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, et al. Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation. Retrovirology (2013) 10:1-1. doi:10.1186/1742-4690-10-119.
63. Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol Ther (2010) 128:433-44. doi:10.1016/j.pharmthera.2010.08.005.
64. Becker PD, Fiorentini S, Link C, Tosti G, Ebensen T, Caruso A, et al. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine (2006) 24:5269-76. doi:10.1016/j.vaccine.2005.11.008.
65. Giagulli C, Magiera AK, Bugatti A, Caccuri F, Marsico S, Rusnati M, et al. HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood (2012) 119:2274-83. doi:10.1182/blood-2011-06-364083.
66. Kampik D, Schulte R, Autenrieth IB. Yersinia enterocolitica invasin protein triggers differential production of interleukin-1, interleukin-8, monocyte chemoattractant protein 1, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor alpha in epithelial cells: implications for understanding the early cytokine network in Yersinia infections. Infect Immun (2000) 68:2484-92. doi:10.1128/IAI.685.2484-2492.2000.
67. Ding J, Chang TL. TLR2 activation enhances HIV nuclear import and infection through T cell activation-independent and-dependent pathways. J Immunol (2012) 188:992-1001. doi:10.4049/jimmunol.1102098.
68. Mackelprang RD, Bigham AW, Celum C, de Bruyn G, Beima-Sofie K, John-Stewart G, et al. Toll-like receptor polymorphism associations with HIV-1 outcomes among Sub-Saharan Africans. J Infect Dis (2014) 209:1623-7. doi:10.1093/infdis/jit807.
69. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 326:711-3. doi:10.1038/326711a0.
70. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik S-G, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell (2007) 130:1071-82. doi:10.1016/j.cell.2007.09.008.
71. Kang JY, Lee J-O. Structural biology of the toll-like receptor family. Annu Rev Biochem (2011) 80:917-41. doi:10.1146/annurev-biochem-052909-141507.
72. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog (2010) 6:e1000852. doi:10.1371/journal.ppat.1000852.
73. Borghi P, Fantuzzi L, Varano B, Gessani S, Puddu P, Conti L, et al. Induction of interleukin-10 by human immunodeficiency virus type 1 and its gp120 protein in human monocytes/macrophages. J Virol (1995) 69:1284-7.
74. Schneider J, Kaaden O, Copeland TD, Oroszlan S, Hunsmann G. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol (1986) 67(Pt 11):2533-8. doi:10.1099/0022-1317-67-11-2533.
75. Booth AM, Fang Y, Fallon JK, Yang J-M, Hildreth JEK, Gould SJ. Exosomes and HIV gag bud from endosome-like domains of the T cell plasma membrane. J Cell Biol (2006) 172:923-35. doi:10.1083/jcb.200508014.
76. Ferrucci A, Nonnemacher MR, Wigdahl B. Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis. Adv Virus Res (2011) 81:165-99. doi:10.1016/B978-0-12-385885-6.00010-9.
77. Hoshino S, Sun B, Konishi M, Shimura M, Segawa T, Hagiwara Y, et al. Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Res Hum Retroviruses (2007) 23:391-7. doi:10.1089/aid.2006.0124.
78. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 67:2182-90.